Zimislecel (formerly VX-880), has shown remarkable early results, setting the stage for the therapy to enter a pivotal-stage trial. At 23.8 times forward earnings, Vertex stock trades in line with ...

Vertex forecasts ... Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its cystic fibrosis drugs and early contributions ...

Vertex Pharmaceuticals Incorporated (NASDAQ ... The PDUFA date is set for January 30, 2025, positioning Vertex for a potential early-2025 launch. Analysts are particularly interested in the ...

Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price ...